Namely, we used a predefined protocol with new-initiators design, defined specific outcomes, used an insulin comparator that is also indicated in advanced stages of type 2 diabetes, and applied PS matching to balance the cohorts. The gene discussed is INS; the disease is type 2 diabetes mellitus.